Media.Player

In Vitro Diagnostic Tests for Predicting New Cardiovascular Events

Technology Application

Using an algorithm, the markedly improved risk prediction can be determined. Also, the invention describes a novel high-throughput assay to measure Lp-PLA2 on isolated Lp(a) particles or isolated apoB particles. Currently, the technique to detect Lp-PLA2 is done in plasma. This invention proposes to have a plate assay to capture Lp-PLA2 using specific antibodies to measure the particles. It is the use of the assay to detect Lp-PLA2 that is unique; the assay has been developed but has not yet been clinically evaluated.

Detailed Technology Description

This invention demonstrates that by measuring the OxPL/apo-B levels and Lp-PLA2 mass (or activity) one obtains complementary and synergistic information with a significant increase in the "hazard ratio" for predicting new cardiovascular events. In addition, if you measure the lipoprotein (a) and the Lp-PLA2 mass, and analyze the data together you get similar information. Therefore, by doing these combined measurements simultaneously, you can determine a higher risk if new cardiovascular events. When a patient presents to a physician, the physician would order both an OxPL/apo-B level (and or Lp(a) ) and an Lp-PLA2 mass.

Supplementary Information

Patent Number: US7939287B2
Application Number: US2009465930A
Inventor: Tsimikas, Sotirios | Witztum, Joseph
Priority Date: 14 May 2008
Priority Number: US7939287B2
Application Date: 14 May 2009
Publication Date: 10 May 2011
IPC Current: C12Q000160
US Class: 435011 | 43500611 | 514824 | 435006
Assignee Applicant: The Regents of the University of California
Title: Methods of identifying a subject having or at risk of having or developing coronary artery disease
Usefulness: Methods of identifying a subject having or at risk of having or developing coronary artery disease
Summary: The methods and kits are useful for determining a subject's predisposition to coronary artery disease, and for identifying a subject having or at risk of having or developing a cardiovascular disease and/or a cardiovascular event (all claimed).
Novelty: Determining a subject's predisposition to coronary artery disease comprises determining the subject's plasma oxidized phospholipids level and lipoprotein-associated phospholipase A2 mass or activity

Industry

Disease Diagnostic/Treatment

Sub Category

Other Disease

Application No.

7939287

Others

Tech ID/UC Case

19635/2007-261-0

Related Cases

2007-261-0

*Abstract

None

*IP Issue Date

May 10, 2011

*Principal Investigator

Name: Sotirios Tsimikas

Department:

Name: Joseph Witztum

Department:

Country/Region

USA